Wheatland Advisors Inc. maintained its position in West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,600 shares of the medical instruments supplier’s stock at the end of the second quarter. Wheatland Advisors Inc.’s holdings in West Pharmaceutical Services were worth $529,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of WST. Vanguard Group Inc. raised its position in West Pharmaceutical Services by 6.5% in the first quarter. Vanguard Group Inc. now owns 6,440,844 shares of the medical instruments supplier’s stock valued at $525,637,000 after buying an additional 392,516 shares during the last quarter. BlackRock Inc. raised its position in West Pharmaceutical Services by 8,884.7% in the first quarter. BlackRock Inc. now owns 5,805,036 shares of the medical instruments supplier’s stock valued at $473,749,000 after buying an additional 5,740,426 shares during the last quarter. JPMorgan Chase & Co. raised its position in West Pharmaceutical Services by 10.1% in the first quarter. JPMorgan Chase & Co. now owns 2,031,582 shares of the medical instruments supplier’s stock valued at $165,798,000 after buying an additional 186,692 shares during the last quarter. Eagle Asset Management Inc. raised its position in West Pharmaceutical Services by 5.6% in the first quarter. Eagle Asset Management Inc. now owns 1,332,389 shares of the medical instruments supplier’s stock valued at $108,736,000 after buying an additional 70,547 shares during the last quarter. Finally, Hermes Investment Management Ltd. raised its position in West Pharmaceutical Services by 0.8% in the first quarter. Hermes Investment Management Ltd. now owns 949,801 shares of the medical instruments supplier’s stock valued at $77,513,000 after buying an additional 7,628 shares during the last quarter. 91.35% of the stock is owned by institutional investors.

West Pharmaceutical Services, Inc. (NYSE:WST) opened at 86.36 on Thursday. West Pharmaceutical Services, Inc. has a 1-year low of $70.17 and a 1-year high of $99.91. The stock has a market capitalization of $6.39 billion, a price-to-earnings ratio of 37.06 and a beta of 1.10. The firm’s 50-day moving average is $92.61 and its 200 day moving average is $88.81.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The company had revenue of $397.60 million during the quarter, compared to analysts’ expectations of $406 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.59 EPS. Equities analysts anticipate that West Pharmaceutical Services, Inc. will post $2.69 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Wednesday, October 18th will be issued a $0.14 dividend. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 annualized dividend and a yield of 0.65%. The ex-dividend date of this dividend is Tuesday, October 17th. West Pharmaceutical Services’s dividend payout ratio is presently 22.22%.

TRADEMARK VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/wheatland-advisors-inc-has-529000-stake-in-west-pharmaceutical-services-inc-nysewst/1470052.html.

Several research analysts have commented on WST shares. Zacks Investment Research lowered shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Jefferies Group LLC reaffirmed a “hold” rating and set a $90.00 price objective (up from $82.00) on shares of West Pharmaceutical Services in a research note on Friday, April 28th. Finally, BidaskClub lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $90.18.

In other West Pharmaceutical Services news, CFO William J. Federici sold 54,996 shares of the company’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $95.45, for a total value of $5,249,368.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.90% of the stock is owned by corporate insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.